Compare iShares China Large-Cap ETF (FXI) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Koninklijke Philips NV — how do they compare? iShares China Large-Cap ETF trades at $33.9 (market cap $3.86B), while Koninklijke Philips NV trades at $24.32 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 6.1× iShares China Large-Cap ETF's market cap, and Koninklijke Philips NV pays a 4.17% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and Koninklijke Philips NV for 84 Days on average.
| FXI | PHG | |
|---|---|---|
Market Cap | $3.86B | $23.52B |
Volume | 16,323,837 | 1,635,069 |
52-Week High | $41.08 | $32.91 |
52-Week Low | $31.59 | $23.81 |
Typical Hold Time | 149 Days | 84 Days |
Sector | — | Health |
Enterprise Value | — | $29.87B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $33.42, down 1.04% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges and trade tensions, though it trades at a significant discount to U.S. equities with a P/E of 11.10 versus the S&P 500's 22.54. Recent geopolitical developments from the Trump-Xi summit and China's export dynamics create mixed sentiment.
The outlook remains cautious with technical indicators signaling selling pressure, while fundamental valuation appears attractive for risk-tolerant investors seeking China exposure. Key risks include ongoing U.S.-China tensions, China's industrial overcapacity, and weak domestic consumption that could limit upside potential despite the valuation discount.
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
